BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
High Court weighs Assenheim appeal over release of Feldstein interview raw footage - 2China Just Got Another Cheap EV America Would Love to Have
- 3See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 4Elite Execution Gaming PCs for Gamers
- 5A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Vote in favor of your Favored kind of footwear
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- EU waters down plans to end new petrol and diesel car sales by 2035
- 6 Fledgling Cameras for 2024: Ideal for New Photographic artists
- What were the little white pills found in Tiger Woods's pocket at the scene of his crash? What to know about hydrocodone.
- Accor signs agreement to transform El Gouna resort as Sofitel
- Reveal Less popular Authentic Realities You Didn't Learn in School
- 6 Exercises to Anticipate in 2024
- NASA releases new photos of interstellar comet 3I/ATLAS
